Prognostic factors in multiple sclerosis

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 449-463

  Kantarci, Orhun H ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056678797     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (86)

1. TheIFNß Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:6655-661.
2. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin in Neurol 1997; 10:186-192.
3. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6:259-274.
4. Weinshenker BG. The natural history of multiple sclerosis: Update 1998. Semin Neurol 1998; 18(3):301-307.
5. Siva A, Kantarci O. An introduction to the clinical spectrum of inflammatory demyelinating disorders of the central nervous system. In: Siva A, Kesselring J, Thompson A, eds. Frontiers in Multiple Sclerosis, vol II. London: Martin Dunitz, 1999, pp 1-9.
6. Allen IV. Asymptomatic multiple sclerosis: what does it mean? In: Siva A, Kesselring J, Thompson A, eds. Frontiers in Multiple Sclerosis, vol II. London: Martin Dunitz, 1999, pp 11-15
7. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. In: Poser CM, Paty DW, Scheinberg L, Ebers GC, eds. The Diagnosis of Multiple Sclerosis. New York: Thieme-Stratton, 1984, pp 224-229.
8. Weinshenker BG, Lucchinetti CF. Acute leukoencephalopathies: Differential diagnosis and investigation. Neurologist 1998; 4:148-166.
9. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: A 5-year follow-up study. Brain 1993; 116:135-146.
10. Söderström M, Ya-Ping Jin, Hillert J, Link H. Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF and HLA findings. Neurology 1998; 50(3):708-714.
11. O’Riordan JI, Thompon AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: A 10-year follow-up. Brain 1998; 121:495-503.
12. Sailer M, O’Riordan J, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52(3):599-606.
13. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997; 49:1404-1413.
14. Lucchinetti CF, Kiers L, O’Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49:1413-1418.
15. Miller DH, Newton MR, Van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 1998; 38:175-179.
16. Kapoor R, Miller DH, Jones SJ, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998; 50(1):230-237.
17. Monteiro LM, Correia M. Benign relapsing meningomyelitis. J Neurol Neurosurg Psychiatry 1991; 54:939-940.
18. Tippet DS, Fishman PS, Panitch HS. Relapsing transverse myelitis. Neurology 1991; 41:703-706.
19. Jeffrey DR, Mandler RN, Davis LE. Transverse myelitis-Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch of Neurol 1993; 50:532-535.
20. Scott TF, Bhagavatula K, Snyder PJ, Chieffe C. Transverse myelitis: Comparison with spinal cord presentations of multiple sclerosis. Neurology 1998; 50(2):429-433.
21. Lipton HL, Teasdall RD. Acute transverse myelopathy in adults: A follow-up study. Arch Neurol 1973; 28:252-257.
22. Campi A, Filippi M, Comi G, et al. Acute transverse myelopathy: Spinal and cranial MR study with clinical follow-up. AJNR 1995; 16:115-123.
23. Austin SG, Zee CS, Waters C. The role of magnetic resonance imaging in acute transverse myelitis. Can J Neurol Sci 1992; 19:508-511.
24. Choi KH, Lee KS, Chung SO, et al. Idiopathic transverse myelitis: MR charactersistics. AJNR 1996; 17(6):1151-60.
25. Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42:250-252.
26. Shibasaki H, Kuroda Y, Kuroiwa Y. Clinical studies of multiple sclerosis in Japan: Classical multiple sclerosis and Devic’s disease. J Neurol Sci 1974; 23:215-222.
27. O’Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60:382-387.
28. Wingerchuk DM, Hogencamp WF, O’Brien PS, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53:1107-1114.
29. Weinshenker BG, O’Brian PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46(6): 878-886.
30. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39(9): 1143-1149.
31. Johnson MD, Lavin P, Whetsell WO, Jr. Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry 1990; 53:918-921.
32. Giubilei F, Sarrantonio A, Tisei P, et al. Four-year follow-up of a case of acute multiple sclerosis of the Marburg type. Ital J Neurol Sci 1997; 18:163-166.
33. Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990; 113:291-302.
34. Revel MP, Valiente E, Gray F, et al. Concentric MR patterns in multiple sclerosis: Report of two cases. J Neuroradiol 1993; 20(4):252-7.
35. Bolay H, Karabudak R, Tacal T et al. Balo’s concentric sclerosis: Report of two patients. J Neuroimaging 1996; 6:98-103.
36. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis-A study of 31 patients. Ann Neurol 1993; 33:18-27.
37. Thompson AJ. Differences between primary and secondary progressive multiple sclerosis. In: Siva A, Kesselring J, Thompson A, eds. Frontiers in Multiple Sclerosis, vol II. London: Martin Dunitz, 1999, pp 29-36.
38. Olerup O, Hillert J. HLA class II associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens 1991; 38:1-15.
39. Weinshenker B, Santrach P, Bissonet AS, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: A population-based study. Neurology 1998; 51: 742-747.
40. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193-96.
41. Bronnum-Hansen H, Koch Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: A nationwide, long-term epidemiologic survey. Neurology 1994; 44:1901-1907.
42. Levic ZM, Dujmovic I, Pekmezovic T, et al. Prognostic factors for survival in multiple sclerosis. Mult Scler 5(3):171-178, 1999.
43. Kurtzke JF. Rating neurological impairment in MS: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33:1444-1452.
44. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin North Amer 1995; 13(1):119-146.
45. Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis: Early prognostic features of the later course of the illness. J Chronic Dis 1977; 30:819-830.
46. Confavreux C, Aimared G, Devic M. Course and prognosis of multiple sclerosis assessed by computerized data processing of 349 patients. Brain 1980; 103:281-300.
47. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990; 113:1597-1628.
48. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: A geographically based study-III. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114:1045-1056.
49. Riise T, Gronning M, Fernandez O, et al. Early prognostic factors for disability in multiple sclerosis: A European multicenter study. Acta Neurol Scand 1992; 85:212-218.
50. Runmarker B, Andersson O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years follow-up. Brain 1993; 116:117-134.
51. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O’Brian PC, Kurland LT. Impairment, disability and handicap in multiple sclerosis: A population based study in Olmsted County, Minnesota. Neurology 1994; 44:28-33.
52. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Neurology 1998; 51:765-772.
53. Thompson AJ. Benign multiple sclerosis (editorial; comment). J Neurology Neurosurg Psychiatry 1999; 67(2):138.
54. Confavreux C. Clinical predictive factors in multiple sclerosis. In: Siva A, Kesselring J, Thompson A, eds. Frontiers in Multiple Sclerosis, vol II. London: Martin Dunitz, 1999, pp 63-66.
55. Lublin FD, Reingold SC. The National Multiple Sclerosis Society (USA; Advisory Commitee on Clinical Trials of New Agents in Multiple Sclerosis). Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46:907-991.
56. Confavreux C. Presentation at the 13th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. ECTRIMS. Istanbul. Turkey, 1997
57. Revesz T, Kidd D, Thompson A, Barnard R. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117:759-765.
58. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121:3-24.
59. Keiper MD, Grossman RI, Hirsch JA, et al. MR identification of white matter abnormalities in multiple sclerosis: A comparison between 1.5 T and T. AJNR 1998; 19:1489-1493.
60. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998; 50(5):1289-1293.
61. Lynch SG, Rose JW, Smoker W, Petajan JH. MRI in familial multiple sclerosis. Neurology 1990; 40:900-903.
62. Filippi M. Magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions. Neurology 1999; 53(5 suppl 3):S18-S22.
63. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991; 41:1251-1256.
64. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonal WI, Miller DH. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63:736-742.
65. Leary SM, Davie CA, Parker GJM, MacManus DG, Miller DH, Thompson AJ. 1H magnetic resonance spectroscopy of normal appearing white matter in primary multiple sclerosis. Ann Neurol 1998; 44:464.
66. Losseff N, Webb S, O’Riordan J, et al. Spinal cord atrophy and disability in multiple sclerosis: A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119:701-708.
67. Losseff N, Wang L, Lai H, Yoo D, et al. Progressive cerebral atrophy in multiple sclerosis: A serial MRI study. Brain 1996; 119:2009-2019.
68. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285.
69. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121:103-113.
70. Filippi M, Rocca MA, Minicucci L, et al. Magnetization transfer imaging of patients with definite MS and negative conventional MRI. Neurology 1999; 52:845-848.
71. Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS. A clinical and MRI cross-sectional study. Neurology 1999; 52:839-845.
72. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhancing magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 353(9157): 964-9.
73. Robertson NP, Compston AS. Prognosis in multiple sclerosis: genetic factors. In Siva A, Kesselring J, Thompson A, eds., Frontiers in Multiple Sclerosis, vol II. London: Martin Dunitz, 1999, pp 51-61.
74. Weinshenker BG, Bulman D, Carriere W, Baskerville J, Ebers GC. A comparison of sporadic and familial multiple sclerosis. Neurology 1990; 40:1354-1358.
75. Robertson NP, Clayton D, Fraser M, Deans J, Compston DAS. Clinical concordance in sibling pairs with multiple sclerosis. Neurology 1996; 47:347-352.
76. Brassat D, Azais-Vuillemin C, Yaouanq J, et al. Familial factors influence disability in MS multiplex families. Neurology 1999; 52:1632-1636.
77. Weinshenker B, Santrach P, Bissonet AS, et al. Major histocompatibility complex class II alleles and the course and outcome of MS. A population-based study. Neurology 1998; 51: 742-747.
78. De la Concha EG, Arroyo R, Crusius JBA, et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele-2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 1997; 80:172-178.
79. Schrijver HM, Crusius JBA, Uitdehaag BMJ, et al. Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999; 52(3): 595-599.
80. Kantarci O, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1ß and IL-1receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000; 106:220-227.
81. Sciacca FL, Ferri C, Vandenbroeck K, et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999; 52:1896-1898.
82. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon 4 allele with disease activity in multiple sclerosis. Neurol Neurosurg Psychiatry 1999; 67(2):203-205.
83. Sylantiev C, Chapman J, Chilkevich O, Nisipeanu P, Chistik V, Korczyn AD. The APOE 4 allele and progression of disability in multiple sclerosis. Neurology 1998; 50(4 suppl. 4): A150.
84. Myhr KM, Raknes G, Nyland H, Vedeler C. Immunoglobulin G Fc-receptor (FCgR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999; 52:1771-1776.
85. Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 1997; 49(2):378-85.
86. Weinshenker BG, Hebrink D, Wingerchuk DM, Klein CJ, Atkinson E, O’Brien PC, McMurray CT. Genetic variants in the tumor necrosis factor receptor 1gene in patients with MS. Neurology 1999; 52(7):1500-1503.